METASTATIC PANCREATIC CANCER (MPC): CONTRAST OF SHORT- (STS) AND LONG TERM (LTS) SURVIVOR CHARACTERISTICS

415Background: MPC is associated with 6-12 month (mo) median overall survival (OS) in published clinical series. However, there is wide variability in OS using standard chemotherapy (CTX) regimens (e.g. gemcitabine/nab-paclitaxel, FOLFIRINOX). 10-20% of patients (pts) live ≤ 3 mo (STS); conversely 5-10% pts live ≥ 24 mo (LTS). We examined pretreatment characteristics of our institutional MPC population for their association with STS/LTS. Methods: From our institutional database, we identified over 400 pts with MPC who received CTX between the years 2003 and 2015. Pts who 1) received all of their CTX at our institution 2) had complete longitudinal follow- up available and 3) lived either ≤ 3 or ≥ 24 mo were further analyzed. A number of pretreatment characteristics were considered, including A) patient and B) disease-related factors. Results: To date,37 pts (median OS 2.0 mo)/ 41 pts (median 28.2 mo) have been identified as STS/LTS respectively. In univariate analysis factors significantly associated with ...